NASDAQ : AVDL
$0 (0.0%)
NASDAQ
Gregory J. Divis Jr.
Drug Manufacturers - Specialty & Generic
Healthcare
AVDL
188
IE
USD
353 1 901 5201
05337M104
0001012477
0.38
2.76
2.37
1.28
0.00
$169.12M
10.72
21.39
77.14
0.28
-$0.51
-$48.83M
2.41%
0.86%
5.44%
2.39%
431.08
0.66
0.66
$20.00
$30.00
$18.50
0/5
14 Analysts
8.20%
9.06
4/9
$109.74M
$199.45M
$101.22M
$6.45M
$2.08B
10.51
177.56
2.76
5.44%
5.68%
0.23%
1.30%
$1.06
540 days
| Name | Title |
|---|---|
| Thomas S. McHugh | Senior Vice President, Principal Financial and Accounting Officer & Chief Financial Officer |
| Jerad G. Seurer | General Counsel, Company Secretary & Compliance Officer |
| Jennifer Gudeman | Senior Vice President of Medical & Clinical Affairs |
| Marla Scarola | Senior Vice President of Regulatory & Quality |
| Jason Vaughn | Senior Vice President of Technical Operations |
| Polly A. Murphy | Chief Business Officer |
| Gregory J. Davis | Vice President of Corporate and Business Development |
| Angie Woods | Vice President of People & Culture |
| Gregory J. Divis Jr. | Chief Executive Officer & Director |
| Susan Rodriguez | Chief Operating Officer |
No votes yet today — be the first to share your view!
About Avadel Pharmaceuticals plc (NASDAQ:AVDL) Stock
Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy. Established in 2015, the entity was formerly recognized as Flamel Technologies SA before rebranding as Avadel Pharmaceuticals plc in January 2017. Its global headquarters are situated in Dublin, Ireland. ...
Alkermes: 'Buy' On Avadel Acquisition And Positive NT2 Data With Alixorexton
2026-06-19 15:49:55
Alkermes plc maintains a Buy rating, driven by the accretive Avadel Pharmaceuticals acquisition and strong pipeline progress. Company bolstered its hypersomnolence portfolio with LUMRYZ, which delivered robust early sales and revenue momentum post-acquisition. Positive phase 2 data for alixorexton in narcolepsy type 2 and ongoing phase 3 Brilliance Studies underpin a compelling growth thesis.
Frequently Asked Questions
What is the current Avadel Pharmaceuticals plc (AVDL) stock price?
Avadel Pharmaceuticals plc(NASDAQ:AVDL) stock price is $21.64 in the last trading session. During the trading session, AVDL stock reached the peak price of $23.57 while $6.38 was the lowest point it dropped to. The percentage change in AVDL stock occurred in the recent session was 0.0% while the dollar amount for the price change in AVDL stock was $0.
AVDL's industry and sector of operation?
The NASDAQ listed AVDL is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
Who are the executives of AVDL?
Thomas S. McHugh
| Senior Vice President, Principal Financial and Accounting Officer & Chief Financial Officer
Jerad G. Seurer
| General Counsel, Company Secretary & Compliance Officer
Jennifer Gudeman
| Senior Vice President of Medical & Clinical Affairs
Marla Scarola
| Senior Vice President of Regulatory & Quality
Jason Vaughn
| Senior Vice President of Technical Operations
How many employees does AVDL have?
Number of AVDL employees currently stands at 188. AVDL operates from 10 Earlsfort Terrace, Dublin, None 2, IE.
Link for AVDL official website?
How do I contact AVDL?
AVDL could be contacted at phone #353 1 901 5201 and can also be accessed through its website. AVDL operates from 10 Earlsfort Terrace, Dublin, None 2, IE.
How many shares of AVDL are traded daily?
The average number of AVDL shares traded daily for last 3 months was 2.42M.
What is the market cap of AVDL currently?
The market value of AVDL currently stands at $2.12B with its latest stock price at $21.64